ArticleJournal of gastrointestinal oncology2025
Andrographolide potentiates anti-tumor immunity in colorectal cancer (CRC) by targeting voltage-dependent anion channel (VDAC) and activating the cGAS-STING axis.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Andrographis restrains the progression of colorectal cancer by inhibiting the KLF3/LEMD1 axis.Functional & integrative genomics · 2026Article
- cGAS-STING Pathway in Gastrointestinal Malignancies: Mechanistic Insights and Translational Therapeutic Opportunities.Journal of gastrointestinal cancer · 2026Review
- Natural Medicines Modulating Tumor Perineural Invasion: Regulatory Mechanisms and Therapeutic Potential.Drug design, development and therapy · 2026Review
- The mitochondrial DNA-cGAS-STING axis in colorectal cancer: a focused review of context-dependent roles and therapeutic opportunities.Frontiers in molecular biosciences · 2026Review
- cGAS-STING signaling: a therapeutic target in inflammatory bowel disease and related colorectal cancer.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a global health burden characterized by significant morbidity and mortality rates. While current therapeutic strategies, including surgical intervention and adjuvant chemotherapy, have shown moderate success, patients with advanced-stage CRC frequently encounter substantial therapeutic obstacles, primarily stemming from acquired drug resistance and tumor immune evasion. Emerging research suggests that phytochemicals are promising therapeutic candidates due to their pleiotropic regulatory capacities, particularly their capability to modulate immune checkpoint inhibitor (ICI) resistance pathways. These bioactive compounds could be used to develop novel therapeutic approaches based on the epigenetic reprogramming of tumor cells and the remodeling of the metabolism-immune crosstalk axis in the tumor microenvironment (TME). This study aimed to investigate the effects and underlying mechanisms of andrographolide in targeting mitochondrial function and remodeling the tumor immune microenvironment in CRC. Methods: This study used Cell Counting Kit-8, live and dead cell staining, immunofluorescence, western blotting, enzyme-linked immunosorbent assay, flow analysis (using CT26 cells), and mouse xenografts to explore the anti-tumor effect and mechanism of andrographolide, a natural product, in CRC. Results: By targeting the voltage-dependent anion channel (VDAC) protein, andrographolide affects the mitochondrial membrane potential of CRC cells, activates the natural immune pathway of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) during tumor proliferation, and reshapes the TME of CRC by recruiting dendric cells, CD4 Conclusions: This study revealed the anti-tumor effect of andrographolide in CRC and the mechanism of immune metabolism regulation. Our findings provide a theoretical basis for the application of natural products in CRC immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.